Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924522 | 0.87 | MEN1 (0.48) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL420503 | 0.87 | CTSK (0.51) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL13100989 | 0.83 | MEN1 (0.56) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL2914776 | 0.82 | KMT2A (0.54) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL6023105 | 0.82 | CTSK (0.50) | MEN1KMT2ASMN1; SMN2CTSKPDK4 | |
| SCHEMBL13101483 | 0.81 | HTR2C (0.49) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL10189350 | 0.81 | MEN1 (0.53) | NPC1RAB9AMEN1KMT2ANPSR1 | |
| SCHEMBL2918265 | 0.79 | ALDH1A1 (0.50) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL4850529 | 0.79 | HTR2C (0.45) | NPC1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL2914778 | 0.78 | KMT2A (0.50) | NPC1RAB9AL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534292-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20050256105-A1 | Cysteine protease and serine protease inhibitors; arthritis, parasite infections, osteoporosis, gingivitis; e.g. benzofuran-2-carboxylic acid [(S)-1-((S)-1-cyclohexylmethyl-3,7-dioxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide | JEONG JAE U | 2005-11-17 | — | — | US | disclosed |
| EP-1534292-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2003099844-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256105-A1 | Cysteine protease and serine protease inhibitors; arthritis, parasite infections, osteoporosis, gingivitis; e.g. benzofuran-2-carboxylic acid [(S)-1-((S)-1-cyclohexylmethyl-3,7-dioxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide | PRSS1, SPINT2, CTRL | NPC1 1448/4885RAB9A 2054/4885L3MBTL1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.